综合康复前注射肉毒毒素对痉挛型脑瘫步行儿童无附加价值
主要终点12周时两组在运动损害、步态参数和目标达成上无显著差异,仅股直肌捕获角在单纯康复组更优(12°,95%CI 2:23,p=0.025)。结论认为综合康复前使用BoNT-A未增加临床疗效,应重新审视该亚组的BoNT-A使用。
要点
- 12周时两组主要结局无显著差异,仅股直肌捕获角在单纯康复组更优。
- 24周随访结果与主要终点相似,BoNT-A未显示附加获益。
- 该年龄段和GMFCS亚组中,BoNT-A处方与使用应被批判性重新考虑。
核心结论
- 在群体水平,综合康复前注射BoNT-A未增加康复的临床疗效。
- 该脑瘫年龄和GMFCS亚组中,BoNT-A的处方与使用应被批判性重新考虑。
研究设计与样本
- 多中心比较试验,两组均接受综合康复(高强度功能物理治疗及指示性石膏/矫形器)。
主要发现
- 主要终点12周时,除股直肌捕获角外,两组治疗效应无统计学显著差异。
- 股直肌捕获角差异为12°(95%CI 2:23,p=0.025),有利于未用BoNT-A的综合康复组。
- 24周随访结果与主要终点相似。
关键数值与推荐
- 股直肌捕获角组间差异12°(95%CI 2:23,p=0.025),有利于未用BoNT-A的综合康复组。
临床怎么用
- 对该年龄段和GMFCS亚组的痉挛型脑瘫步行儿童,综合康复前加用BoNT-A未显示附加临床获益。
- 处方BoNT-A时应结合本试验结果批判性评估其必要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Botulinum toxin (BoNT-A) is widely used in combined treatment for spastic cerebral palsy, but its added value preceding comprehensive rehabilitation for motor impairments, gait, and goal attainment has not been studied. DESIGN: A comparative multi-centre trial, in which two groups underwent comprehensive rehabilitation (i.e. high-intensive functional physiotherapy, and indicated casting/orthoses). One group received intramuscular BoNT-A prior to rehabilitation, and the other group did not receive BoNT-A. SUBJECTS/PATIENTS: Children with spastic cerebral palsy, Gross Motor Function Classification System (GMFCS) levels I-III, age range 4-12 years, indicated for BoNT-A treatment regarding mobility problems. METHODS: Sixty-five children participated (37 boys), mean age 7.3 years (standard deviation (SD) 2.3, range 4-12 years), equally distributed across GMFCS levels. Forty-one children received BoNT-A+ comprehensive rehabilitation and 24 received comprehensive rehabilitation only. Functional leg muscle strength, passive range of motion, angle of catch, cerebral palsy-related pain, walking speed, kinematic gait parameters, goal attainment, and proxy-reported general functioning were assessed at baseline, primary end-point (12 weeks) and 24-week follow-up. Statistical analyses were performed with linear mixed models. RESULTS: At the primary end-point there were no statistically significant differences in treatment effects between the groups, except for the angle-of-catch of the rectus femoris, which was in favour of comprehensive rehabilitation without BoNT-A (12° difference, 95% confidence interval (95% CI) 2:23, p = 0.025). Results at follow-up were similar. CONCLUSION: At the group level, treating with BoNT-A prior to comprehensive rehabilitation did not add to the clinical effectiveness of rehabilitation. Thus, BoNT-A prescription and use should be critically reconsidered in this cerebral palsy age- and GMFCS-subgroup.
引用
- Schasfoort F, Pangalila R, Sneekes EM, et al. Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy. J Rehabil Med. 2018. PMID: 30080235. doi:10.2340/16501977-2369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。